Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance

NCT ID: NCT01681264

Last Updated: 2025-11-06

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-09-30
• Study Completion Date: 2023-12-31

Brief Summary

Dual medication (guanfacine and morphine) as a standard treatment for chronic pain.

Detailed Description

This aim proposes that guanfacine would be a useful drug to deter Opioid-Induced Hyperalgesia (OIH) when combined with an opioid (morphine) in chronic pain management.

Conditions

Chronic Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Morphine:Placebo

Group Type: ACTIVE_COMPARATOR

Morphine

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Morphine:Guanfacine 1mg

Group Type: ACTIVE_COMPARATOR

Morphine

Intervention Type: DRUG

Guanfacine 1mg

Intervention Type: DRUG

Morphine:Guanfacine 2mg

Group Type: ACTIVE_COMPARATOR

Morphine

Intervention Type: DRUG

Guanfacine 2mg

Intervention Type: DRUG

Placebo:Guanfacine 2mg

Group Type: ACTIVE_COMPARATOR

Guanfacine 2mg

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Placebo:Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

Morphine

Intervention Type: DRUG

Guanfacine 1mg

Intervention Type: DRUG

Guanfacine 2mg

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Other Intervention Names

MS Contin; Intuniv; Tenex; Intuniv; Tenex; Sugar Pill

Eligibility Criteria

Inclusion Criteria

• 18-65 years old
• Chronic neck or back pain condition for at least 3 months
• VAS score of 4-8
• Has not taken an opioid for the last 3 months
• Has not taken guanfacine (or other alpha-2AR agonists) for the last 6 months

Exclusion Criteria

• Sensory deficits at site of QST, such as peripheral neuropathy
• Allergic to or has had a severe adverse reaction to study medication (i.e. opioids, guanfacine, lactose, vitamin B2 a.k.a. riboflavin)
• Cannot tolerate study drugs' maximum doses
• Takes vitamin B2 > 1.6mg/day during the study
• Pregnant or breastfeeding
• Pending litigation
• Diagnosed with Raynaud's syndrome
• Has other chronic pain conditions such as fibromyalgia or joint osteoarthritis that are predominant over back and neck pain with regard to its intensity (VAS)
• Has known pre-existing cardiovascular disease (i.e. arrhythmia - prolonged QT interval > 440ms), cerebrovascular disease, hepatic or renal impairment, CNS condition, metabolic condition, or history of syncope
• Hypotension (SBP < 90 mmHg and DBP < 60 mmHg for female or SBP < 100 mmHg and DBP < 60 mmHg for male; measured while in a sitting position) or bradycardia (resting heart rate < 60 bpm)
• Subjects are on antihypertensive drugs (e.g., a beta-blocker) that result in hypotension and/or bradycardia as defined above
• Tests positive for non-study opioids, illicit drugs, marijuana, or non-prescribed drugs
• Major psychiatric disorders that required hospitalization in the past 6 months such as: major depression, bipolar disorder, schizophrenia, anxiety disorder, or psychotic disorders
• Currently in a treatment program for alcohol or drug abuse, or currently on methadone or buprenorphine (i.e. suboxone, subutex) for treatment of addiction, or stimulants for treatment of ADHD
• History of substance or alcohol abuse (meets DSM IV criteria) per medical record or subject admission
• Subjects are on medications that serve as CYP3A4/5 inhibitors or CYP3A4 inducers including, but are not limited to, valproic acid, macrolide antibiotics, antifungal drugs, St. John wort, ACE inhibitors, nefazodone (antidepressant), calcium channel blockers, H2-receptor antagonists, anti-HIV or AIDS drugs, and antiepileptic drugs
• Subjects are on medications that are ligands for alpha2-adrenergic receptors including antipsychotic drugs (e.g. clozapine) and tricyclic or tetracyclic antidepressants (e.g. imipramine, mirtazapine, mianserin). Any medications taken by a subject at the enrollment will be reviewed regarding their compatibility with guanfacine and morphine as well as possible confounding side effects. In addition, subjects will be warned of side effects of morphine such as sedation, respiratory depression at the enrollment. Subjects will be allowed to take non-opioid pain medications except for gabapentinoids and amitriptyline/nortriptyline as far as such medications do not have incompatibility with morphine and guanfacine.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institutes of Health (NIH)

NIH

Sponsor Role: collaborator

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role: collaborator

Massachusetts General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Jianren Mao, MD, PhD

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jianren Mao, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Locations

Center for Translational Pain Research

Boston, Massachusetts, United States

Countries

United States

Other Identifiers

1R01DA036564-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

2013P-001510

Identifier Type: -

Identifier Source: org_study_id